See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Christoph Westphal, MD, Ph.D - CEO SIRTRIS (GSK)

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Could Byetta Become a Standalone Drug?

Craig Eberhard

Could Byetta Become a Standalone Drug?

Victoza

Page 2
Novo Says Early Use of Victoza Aids Type 2 Control
Dec 15, 2011 | 
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy Type 2 Diabetes" for more discussion about the phenomenon.)
Novo Says Early Use of Victoza Aids Type 2 Control
Oct 2, 2011 | 
News from Danish pharmaceutical manufacturer Novo Nordisk reinforces the growing trend toward using a two-drug combination in the early treatment of type 2 diabetes. (See "A Conversation About Janumet and Earlier Combination Therapy for Type 2 Diabetes" for more discussion about this phenomenon.) In a study it released in Lisbon, Portugal, at the recent meeting of the European Association for the Study of Diabetes, Novo said that combining its recently released drug Victoza® (liraglutide) with another drug early in therapy helps recently diagnosed type 2s achieve greater blood glucose control than they can with a single drug.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Christoph Westphal, MD, Ph.D - CEO SIRTRIS (GSK)

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Could Byetta Become a Standalone Drug?

Craig Eberhard

Could Byetta Become a Standalone Drug?

World Diabetes Day 2009

DHTV Covers World Diabetes Day in Sacramento, California

World Diabetes Day 2009

Sanofi Says Late-Stage Trial of Type 2 Drug a Success
May 23, 2011 | 
French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
Victoza® Achieved Improved Blood Sugar Control in African-Americans With Type 2 Diabetes
Aug 5, 2010 | 
Novo Nordisk presented results demonstrating that once-daily Victoza® (liraglutide [rDNA] injection) achieved significantly greater improvements in blood sugar control compared to placebo among African-American patients with type 2 diabetes. The meta-analysis of phase 3 data from the Liraglutide Effect and Action in Diabetes (LEAD) trials were presented at the 2010 National Medical Association Annual Convention & Scientific Assembly.
FDA Gives Novo the Go-Ahead to Market Victoza® in the U.S.
Feb 27, 2010 | 
Danish pharmaceutical company Novo Nordisk has received Food and Drug Administration permission to begin marketing its type 2 drug Victoza® in the United States.
Victoza, the brand name for liraglutide, is a GLP-1* analog that is taken one a day by injection to help control blood sugar-and in some cases, help with weight loss-in patients with type 2 diabetes.
Novo Nordisk's Victoza Receives FDA Approval for the Treatment of Type 2 Diabetes
Jan 28, 2010 | 
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Type 2 Drugs: EU Approves “Victoza,” FDA Extends Review of “Onglyza”
May 6, 2009 | 
The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.
Next Page » « Previous Page
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.